Regeneron Pharmaceuticals, Inc. (REGN)

$738

-6.5

(-0.87%)▲

Market is closed - opens 8 PM, 25 Nov 2024
star icon

Regeneron Pharmaceuticals Inc is a biopharmaceutical company that develops and commercializes medicines for serious medical conditions.

Performance

  • $737.93
    $750.97
    $738.00
    downward going graph

    0.01%

    Downside

    Day's Volatility :1.74%

    Upside

    1.73%

    downward going graph
  • $735.95
    $1,211.20
    $738.00
    downward going graph

    0.28%

    Downside

    52 Weeks Volatility :39.24%

    Upside

    39.07%

    downward going graph

Returns

PeriodRegeneron Pharmaceuticals, Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-38.45%
-7.3%
6.3%
6 Months
-24.74%
-0.5%
13.5%
1 Year
-7.55%
10.5%
33.2%
3 Years
13.66%
8.8%
20.5%

Highlights

Market Capitalization
81.8B
Book Value
$272.04
Earnings Per Share (EPS)
40.43
PE Ratio
18.41
PEG Ratio
1.11
Wall Street Target Price
1078.11
Profit Margin
33.61%
Operating Margin TTM
33.43%
Return On Assets TTM
7.41%
Return On Equity TTM
17.17%
Revenue TTM
13.8B
Revenue Per Share TTM
128.69
Quarterly Revenue Growth YOY
10.6%
Gross Profit TTM
7.0B
EBITDA
4.6B
Diluted Eps TTM
40.43
Quarterly Earnings Growth YOY
0.3
EPS Estimate Current Year
44.91
EPS Estimate Next Year
45.32
EPS Estimate Current Quarter
11.69
EPS Estimate Next Quarter
11.77

Analyst Recommendation

Buy
    76%Buy
    20%Hold
    2%Sell
Based on 34 Wall street analysts offering stock ratings for Regeneron Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
26
26
26
Hold
7
7
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 46.09%

Current $738.00
Target $1,078.11

Company Financials

FY18Y/Y Change
Revenue
6.7B
↑ 14.28%
Net Income
2.4B
↑ 103.95%
Net Profit Margin
36.42%
↑ 16.01%
FY19Y/Y Change
Revenue
7.9B
↑ 17.18%
Net Income
2.1B
↓ 13.44%
Net Profit Margin
26.91%
↓ 9.51%
FY20Y/Y Change
Revenue
8.5B
↑ 8.06%
Net Income
3.5B
↑ 66.05%
Net Profit Margin
41.35%
↑ 14.44%
FY21Y/Y Change
Revenue
16.1B
↑ 89.14%
Net Income
8.1B
↑ 129.86%
Net Profit Margin
50.25%
↑ 8.9%
FY22Y/Y Change
Revenue
12.2B
↓ 24.26%
Net Income
4.3B
↓ 46.28%
Net Profit Margin
35.64%
↓ 14.61%
FY23Y/Y Change
Revenue
13.1B
↑ 7.76%
Net Income
4.0B
↓ 8.87%
Net Profit Margin
30.14%
↓ 5.5%
Q2 FY23Q/Q Change
Revenue
3.2B
↓ 0.13%
Net Income
968.4M
↑ 18.42%
Net Profit Margin
30.66%
↑ 4.8%
Q3 FY23Q/Q Change
Revenue
3.4B
↑ 6.48%
Net Income
1.0B
↑ 4.07%
Net Profit Margin
29.97%
↓ 0.69%
Q4 FY23Q/Q Change
Revenue
3.4B
↑ 2.13%
Net Income
1.2B
↑ 15.06%
Net Profit Margin
33.77%
↑ 3.8%
Q1 FY24Q/Q Change
Revenue
3.1B
↓ 8.42%
Net Income
722.0M
↓ 37.74%
Net Profit Margin
22.96%
↓ 10.81%
Q2 FY24Q/Q Change
Revenue
3.5B
↑ 12.79%
Net Income
1.4B
↑ 98.38%
Net Profit Margin
40.38%
↑ 17.42%
Q3 FY24Q/Q Change
Revenue
3.7B
↑ 4.89%
Net Income
1.3B
↓ 6.4%
Net Profit Margin
36.03%
↓ 4.35%
FY18Y/Y Change
Total Assets
11.7B
↑ 33.89%
Total Liabilities
3.0B
↑ 13.62%
FY19Y/Y Change
Total Assets
14.8B
↑ 26.17%
Total Liabilities
3.7B
↑ 24.8%
FY20Y/Y Change
Total Assets
17.2B
↑ 15.93%
Total Liabilities
6.1B
↑ 65.2%
FY21Y/Y Change
Total Assets
25.4B
↑ 48.19%
Total Liabilities
6.7B
↑ 8.6%
FY22Y/Y Change
Total Assets
29.2B
↑ 14.86%
Total Liabilities
6.6B
↓ 1.73%
FY23Y/Y Change
Total Assets
33.1B
↑ 13.23%
Total Liabilities
7.1B
↑ 8.5%
Q2 FY23Q/Q Change
Total Assets
30.7B
↑ 1.99%
Total Liabilities
6.6B
↑ 1.14%
Q3 FY23Q/Q Change
Total Assets
32.2B
↑ 4.91%
Total Liabilities
7.3B
↑ 9.33%
Q4 FY23Q/Q Change
Total Assets
33.1B
↑ 2.85%
Total Liabilities
7.1B
↓ 2.09%
Q1 FY24Q/Q Change
Total Assets
34.4B
↑ 3.9%
Total Liabilities
7.4B
↑ 3.82%
Q2 FY24Q/Q Change
Total Assets
36.1B
↑ 5.0%
Total Liabilities
7.9B
↑ 6.81%
Q3 FY24Q/Q Change
Total Assets
37.4B
↑ 3.76%
Total Liabilities
8.1B
↑ 2.98%
FY18Y/Y Change
Operating Cash Flow
2.2B
↑ 67.94%
Investing Cash Flow
-1.5B
↑ 45.55%
Financing Cash Flow
-77.1M
↑ 215.98%
FY19Y/Y Change
Operating Cash Flow
2.4B
↑ 10.7%
Investing Cash Flow
-2.0B
↑ 38.61%
Financing Cash Flow
-252.1M
↑ 226.98%
FY20Y/Y Change
Operating Cash Flow
2.6B
↑ 7.74%
Investing Cash Flow
-70.6M
↓ 96.52%
Financing Cash Flow
-2.0B
↑ 681.63%
FY21Y/Y Change
Operating Cash Flow
7.1B
↑ 170.47%
Investing Cash Flow
-5.4B
↑ 7527.05%
Financing Cash Flow
-1.0B
↓ 48.96%
FY22Y/Y Change
Operating Cash Flow
5.0B
↓ 29.18%
Investing Cash Flow
-3.8B
↓ 29.72%
Financing Cash Flow
-1.0B
↑ 0.32%
Q2 FY23Q/Q Change
Operating Cash Flow
1.0B
↓ 25.24%
Investing Cash Flow
-2.4B
↑ 912.69%
Financing Cash Flow
-614.2M
↑ 90.45%

Technicals Summary

Sell

Neutral

Buy

Regeneron Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-21.61%
-24.74%
-7.55%
13.66%
101.19%
Biontech Se
Biontech Se
1.94%
14.27%
14.47%
-63.37%
445.2%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-16.95%
63.94%
50.31%
30.85%
117.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.06%
0.04%
27.74%
141.35%
101.98%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.41
18.41
1.11
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.53
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.8B
101.19%
18.41
33.61%
Biontech Se
Biontech Se
Buy
$25.9B
445.2%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.8B
117.83%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.0B
101.98%
32.84
-4.51%

Insights on Regeneron Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 3.14B → 3.72B (in $), with an average increase of 8.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.43B → 1.34B (in $), with an average decrease of 6.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.3% return, outperforming this stock by 58.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 30.9% return, outperforming this stock by 17.2%

Institutional Holdings

  • FMR Inc

    9.43%

  • Vanguard Group Inc

    8.48%

  • BlackRock Inc

    7.69%

  • JPMorgan Chase & Co

    7.53%

  • State Street Corp

    4.41%

  • Capital World Investors

    3.91%

Company Information

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Organization
Regeneron Pharmaceuticals, Inc.
Employees
14165
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Industry
Health Technology

FAQs